Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group

The use of natalizumab for highly active relapsing-remitting multiple sclerosis (MS) is influenced by the occurrence of progressive multifocal leukoencephalopathy (PML). Through measurement of the anti-JCV antibody index, and in combination with the presence or absence of other known risk factors, i...

Descripción completa

Detalles Bibliográficos
Autores principales: McGuigan, C, Craner, M, Guadagno, J, Kapoor, R, Mazibrada, G, Molyneux, P, Nicholas, R, Palace, J, Pearson, O R, Rog, D, Young, C A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Multiple Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752634/
https://www.ncbi.nlm.nih.gov/pubmed/26492930
http://dx.doi.org/10.1136/jnnp-2015-311100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752634/
https://www.ncbi.nlm.nih.gov/pubmed/26492930
http://dx.doi.org/10.1136/jnnp-2015-311100

Ejemplares similares